(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback